2018 was a strong year for our Tiara and Reducer product platforms. Both have achieved significant therapy development milestones, putting Neovasc on a stronger foundation from which to continue advancing these products commercially. We also have a clear value creation strategy for patients, employees, and investors. All of this is really good news for our outlook.
Investor Overview
Latest News
Neovasc Reducer™ Therapy for Refractory Angina Exceeds 200th Patient Milestone in Germany
> read full release
Programs and Events
Stifel Healthcare Conference
Fred Colen's presentation via webcast
Nov. 20, 2019, 4:10 p.m. ESTregister >
13th Annual Cannacord Genuity Forum
Fred Colen's presentation via webcast
Nov. 21, 2019, 10:00 a.m. EST)register >
Neovasc Presentation - November 2019
Financial Report Archives
2019 Financial Reports
News Release Archives
2019 News Releases
Share Information
Auditor
Grant Thornton LLP, Vancouver, BC
Legal Counsel
Blakes LLP, Vancouver, BC
Transfer Agent
Computershare, Vancouver, BC
Investor Relations
Chris Clark, Chief Financial Officer
investors@neovasc.com
To automatically receive news updates